Page last updated: 2024-10-30

leflunomide and Dermatitis, Atopic

leflunomide has been researched along with Dermatitis, Atopic in 7 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Dermatitis, Atopic: A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.

Research Excerpts

ExcerptRelevanceReference
"A subgroup of atopic eczema patients requires systemic immunomodulatory treatment for long time periods."2.44Novel immunological approaches in the treatment of atopic eczema. ( Andres, C; Belloni, B; Mempel, M; Ollert, M; Ring, J, 2008)
"Atopic dermatitis is a chronically relapsing eczematous disease of the skin."2.44Emerging treatment of atopic dermatitis. ( Hsu, CJ; Wang, LF, 2007)
"Atopic dermatitis is a common inflammatory skin condition with increasing incidence in recent decades."2.43Recent developments in the treatment of adult atopic dermatitis. ( Barnetson, RS; Pua, VS, 2006)
"Leflunomide is an immunomodulating and disease-modifying antirheumatic drug with anti-inflammatory and immunosuppressive activity, exhibiting an extremely long in vivo half life."2.43Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data. ( Pfeiffer, C; Vitéz, L; Wozel, G, 2006)
"Leflunomide is a pyrimidine de novo synthesis-inhibiting immunosuppressant exhibiting an extremely long in vivo half life of its active metabolite."1.32Leflunomide as a novel treatment option in severe atopic dermatitis. ( Pfeiffer, C; Schmitt, J; Wozel, G, 2004)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (85.71)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Schmitt, J2
Abraham, S1
Trautmann, F1
Stephan, V1
Fölster-Holst, R1
Homey, B1
Bieber, T1
Novak, N1
Sticherling, M1
Augustin, M1
Kleinheinz, A1
Elsner, P1
Weidinger, S1
Werfel, T1
Belloni, B1
Andres, C1
Ollert, M1
Ring, J1
Mempel, M1
Wozel, G2
Pfeiffer, C2
Kagami, S1
Saeki, H1
Komine, M1
Kakinuma, T1
Tsunemi, Y1
Nakamura, K1
Sasaki, K1
Asahina, A1
Tamaki, K1
Pua, VS1
Barnetson, RS1
Vitéz, L1
Hsu, CJ1
Wang, LF1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis[NCT00931242]Phase 210 participants (Actual)Interventional2009-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Patients Achieving 50% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0

EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks

Interventionparticipants (Number)
Apremilast2

Number of Patients Achieving 75% Reduction in Eczema Area and Severity Index (EASI) Score at Week 12 in Reference to Week 0

EASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, edema, lichenification, and excoriations/erosions are scored on a scale of 0 (none) to 3 (severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 to 6. The total qualitative score is multiplied by the degree of involvement for each anatomic region and then multiplied by a constant and summed to yield the EASI score. (NCT00931242)
Timeframe: 12 weeks

Interventionparticipants (Number)
Apremilast1

Number of Patients Achieving an Improvement (Decrease) in IGA (Investigator Global Assessment) by Two or More Points

Improvement in IGA (Investigator Global Assessment) by two or more points on a five point scale, with 0 being no disease activity and 5 being maximum disease activity, at week 12 (NCT00931242)
Timeframe: 12 weeks

Interventionparticipants (Number)
Apremilast2

Reviews

4 reviews available for leflunomide and Dermatitis, Atopic

ArticleYear
Novel immunological approaches in the treatment of atopic eczema.
    Current opinion in allergy and clinical immunology, 2008, Volume: 8, Issue:5

    Topics: Adult; Antibodies, Monoclonal; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic

2008
Recent developments in the treatment of adult atopic dermatitis.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:2

    Topics: Antibodies, Monoclonal; Calcineurin Inhibitors; Dermatitis, Atopic; Humans; Immunoglobulins, Intrave

2006
Severe atopic dermatitis and leflunomide: first clinical experience and highlights of pertinent experimental data.
    Dermatology online journal, 2006, Mar-30, Volume: 12, Issue:3

    Topics: Adult; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Severity

2006
Emerging treatment of atopic dermatitis.
    Clinical reviews in allergy & immunology, 2007, Volume: 33, Issue:3

    Topics: Androstadienes; Animals; Dermatitis, Atopic; Desensitization, Immunologic; Fluticasone; Histamine H1

2007

Other Studies

3 other studies available for leflunomide and Dermatitis, Atopic

ArticleYear
Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2017, Volume: 15, Issue:1

    Topics: Adult; Alitretinoin; Anti-Inflammatory Agents; Azathioprine; Cyclosporine; Dermatitis, Atopic; Femal

2017
Leflunomide as a novel treatment option in severe atopic dermatitis.
    The British journal of dermatology, 2004, Volume: 150, Issue:6

    Topics: Acute Disease; Adult; Dermatitis, Atopic; Drug Administration Schedule; Humans; Immunosuppressive Ag

2004
Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells.
    Clinical and experimental immunology, 2005, Volume: 141, Issue:3

    Topics: Cell Line, Tumor; Cell Movement; Chemokine CCL26; Chemokines, CC; Culture Media, Conditioned; Dermat

2005